Epidemiology Forecast Report on Gallbladder Cancer in 18 Major Markets
Gallbladder Cancer (GBC) primarily occurs in the gallbladder itself, but also includes the extrahepatic bile duct, Ampulla of Vater and other non-specified biliary duct tumours. It is currently the most common malignant tumour of the biliary tract worldwide, with a very low survival rate. There are currently no known causes for GBC at this point in time.
This report provides the current incidence population for GBC across 18 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Canada, Australia, India, Mexico, Turkey, South Africa, Saudi Arabia, Argentina, Russia and China) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of the stages, locations and histopathology of GBC tumours. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team , several of the main symptoms and co-morbidities of GBC have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for GBC include:
• Obesity
• Chronic cholecystitis
• Choleithiasis
• Gallstones
• Diabetes
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global GBC’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of GBC and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on GBC’s prevalent population.
• Examination of the incidence of the different causative gene mutations for GBC.
• Identify sub-populations within GBC which require treatment.
• Gain an understanding of the specific markets that have the largest number of GBC patients.
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/ Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Gallbladder Cancer Incidence
• Stages and Location of Gallbladder Cancer
o Staging of Gallbladder Cancer
o Histopathology of Tumour Cells in Gallbladder Cancer
o Gallbladder Cancer Tumour Location
• Associated Conditions of Gallbladder Cancer
o BMI Status of Gallbladder Cancer Patients
o Pain-related Conditions Associated with Gallbladder Cancer
o Gene Over-expression in Gallbladder Cancer
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
• AJCC Tumour Staging Classification for Gallbladder Cancer
• Incidence of Gallbladder Cancer, total (000s)
• Incidence of Gallbladder Cancer, males (000s)
• Incidence of Gallbladder Cancer, females (000s)
• AJCC Stages of Gallbladder Cancer patients, total (000s)
• Major Histopathological type in Gallbladder Cancer, total (000s)
• Tumour location in Gallbladder Cancer patients, total (000s)
• BMI of Gallbladder Cancer patients, total (000s)
• Gallstones in Gallbladder Cancer patients, total (000s)
• EGFR in Gallbladder Cancer patients, total (000s)
• p53 in Gallbladder Cancer patients, total (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• USA Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• France Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• France Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Germany Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Germany Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Italy Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Italy Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Spain Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Spain Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• United Kingdom Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• United Kingdom Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Brazil Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Brazil Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Japan Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Japan Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• India Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• India Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Australia Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Australia Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Canada Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Canada Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Mexico Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Mexico Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Turkey Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Turkey Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• South Africa Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• South Africa Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Saudi Arabia Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Saudi Arabia Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Argentina Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Argentina Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• Russia Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• Russia Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
• China Incidence of Gallbladder Cancer by 5-yr age cohort, males (000s)
• China Incidence of Gallbladder Cancer by 5-yr age cohort, females (000s)
+1 888 709 8757
Chat With Us